Table 1.

Baseline characteristics and clinical details regarding the seven patients who underwent exit site relocation by external splicing and cuff removal as rescue catheter treatment for refractory tunnel infection

	ID-1	ID-2	ID-3	ID-4	ID-5	ID-6	ID-7
Sex (M = male; F = female)	F	M	F	M	F	M	M
Age (years)	49	69	81	70	54	55	68
Kidney disease	ADPKD	Unknown	Unknown	Diabetic Neph	Cardiorenal type II	IgA Neph	Membranous Neph
Time on PD (months)	11.4	4.3	17.4	26.2	3.2	15.7	34.4
PRE ATB Therapy	Cepha– > cipro	Cefa– > vanco	Cepha– > cipro	Cephalexin	Cepha– > cipro	Cephalexin	Cepha– > cipro
Microorganism	P. aeruginosa	S. aureus	P. aeruginosa	S. aureus	P. aeruginosa	S. aureus	P. aeruginosa
DUR PRE ATB therapy (days)	28	21	25	19	27	18	24
DIM AREA SUP CUFF (mm)	2.22	2.45	2.31	3.66	2.82	3.81	4.11
MAX DIM AREA PERICAT (mm)	3.24	3.64	3.43	7.82	3.55	4.13	5.43
POST ATB THERAPY	Ciprofloxacin	Vancomycin	Ciprofloxacin	Cephalexin	Ciprofloxacin	Cephalexin	Ciprofloxacin
DUR POST ATB THERAPY (days)	21	21	21	21	21	21	21
Relapse at 12 months	No	No	No	No	No	No	No

ADPKD  autosomal dominant polycystic kidney disease, cepha cephalexin, cipro ciprofloxacin, DIM dimension, DUR duration, Neph nephropathy, ID patient identification number, PRE ATB THERAPY antibiotic therapy prescribed before exit site relocation by external splicing and cuff removal (– >  = shift to other molecule during the antibiotic course), POST ATB THERAPY antibiotic therapy prescribed after the exit site relocation by external splicing and cuff removal, PD peritoneal dialysis, PERICAT pericatheter, vanco vancomycin